Short communication: transmission of hepatitis B viruses with lamivudine resistance mutations in newly diagnosed HIV individuals.
From 1519 newly diagnosed HIV individuals seen in Madrid between the years 2000 and 2008, 65 (4.3%) were HBsAg(+). Two HIV/HBV-coinfected patients showed the lamivudine resistance mutation M204V in HBV while no drug resistance mutations were recognized in HIV. None of them admitted prior exposure to antiretroviral drugs. Thus, HIV/HBV-coinfected patients might benefit from baseline drug resistance testing for both HIV and HBV to optimize the selection of anti-HBV active antiviral therapy.
Treviño
Ana
A
Service of Infectious Diseases, Hospital Carlos III, Hospital de Mostoles, Madrid, Spain.
Soriano
Vincent
V
Madejon
Antonio
A
Rodriguez
Carmen
C
Barros
Carlos
C
Botecchia
Marcelle
M
Tuma
Paula
P
Del Romero
Jorge
J
de Mendoza
Carmen
C
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D024882:Drug Resistance, Viral / Q000235:genetics*; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000821:virology; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000235:genetics*; D019694:Hepatitis B, Chronic / Q000150:complications* / Q000188:drug therapy / Q000635:transmission* / Q000821:virology; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008297:Male; D009154:Mutation
D019380:Anti-HIV Agents; D006514:Hepatitis B Surface Antigens; D019259:Lamivudine